Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2004

View Archived Issues

Promising new antibiotic against drug-resistant Gram-positive and -negative pathogens

Phase IIb RA study of Rituxan meets primary endpoint

Phase II multidose study planned for exenatide LAR in 2005

Approvable letter for Ralivia ER

New anticancer and immunostimulant agent isolated from plants by Japanese team

New inhibitors of PDE4, MMP and/or TNF-alpha discovered at Celgene

Novel ZAP70 and Syk kinase inhibitors under study at Kissei

Pfizer researchers describe new beta2-adrenoceptor agonists and their use

Novel TGF-beta receptor type II kinase inhibitors claimed by Pfizer

Vertex patent covers novel GSK-3 inhibitors and their use in stroke, AD, diabetes, etc.

Novel IgE production inhibitors prepared and tested at Dainippon

Shionogi scientists present new HIV integrase inhibitors

Low-frequency CERA dosing effective in chronic kidney disease patients

SR-121463 beneficial in SIADH patients

Dialysis hypotension improves with FK-352

Studies reveal efficacy of pyridoxamine in diabetic nephropathy

Merck identifies centrally acting allosteric mGluR5 modulators

Natural protease inhibitors may enhance chemotherapeutic efficacy

Novel methionyl tRNA synthetase inhibitor REP-8839 shows potent antibacterial activity

Aldosterone inhibitor may ameliorate hypertension-induced end-organ damage

Schering-Plough and ViroPharma finalize pleconaril license agreement

Sonus to acquire Synt:em

Genzyme seeks additional indication for Thyrogen

Mitsubishi Pharma and Takeda terminate license agreement for oral MCC-135

Taxotere approved in E.U. for prostate cancer

Alza enters into option and license agreement with Ardent for DPI-125

Norak Biosciences in second license agreement with AstraZeneca

spi-VEC oral hepatitis B vaccine shows promise in phase I study

X-Ceptor researchers identify potent and selective inverse agonist of ERRalpha

Good tolerability profile reported for DepoDur after lower abdominal surgery

Two-year results of the TEMPO trial confirm the efficacy of etanercept plus methotrexate in RA

Update on the clinical development of tefibazumab for S. aureus infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...